
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences Inc is experiencing significant growth driven by strong patient demand and an expanding sales force, which will increase by approximately 30% to enhance the adoption of its lead product, Ingrezza. The company reported impressive quarterly results with Ingrezza sales showing a 10% quarter-over-quarter and 12% year-over-year increase, reaching a record high in prescriptions, alongside Crenessity achieving net product sales of $98 million for Q3. Furthermore, with a robust product pipeline and expectations for its key products to generate substantial revenues in the coming years, Neurocrine Biosciences is positioned for meaningful long-term growth despite potential pricing pressures.
Bears say
Neurocrine Biosciences faces significant competition risks that may hinder the growth of its key product, Ingrezza, particularly in the tardive dyskinesia and Huntington's disease chorea markets, which are already serviced by existing approved therapies. The company’s Crenessity launch has not demonstrated durability, with sales plateauing and falling short of ambitious projections due to competitive pressures and potential compliance issues. Additionally, upcoming pricing pressures from the Inflation Reduction Act could further exacerbate risks to Ingrezza's revenue growth, impacting investor sentiment and the overall stock outlook.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares